COVID-19 is associated with a significantly increased long-term risk for incident thyroid dysfunction, including hypothyroidism.

Eye discomfort and vision changes can sometimes signal deeper health issues. Understanding these signs early may help protect ...

Thyroid disorders can affect eye health in multiple ways. Learn why regular eye check-ups are essential, the symptoms of ...

ALBANY, N.Y. (NEWS10) – Women are three times more likely to have thyroid nodules or thyroid cancer, compared to men. Women are also five to ten times more likely to have autoimmune thyroid diseases.

- Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for veligrotug for the treatment of thyroid eye disease (TED). Veligrotug is a ...

TED is an autoimmune disorder distinct from Graves disease, affecting individuals with varying thyroid states and often misdiagnosed, especially in women. Symptoms of TED, such as pain and double ...

The MarketWatch News Department was not involved in the creation of this content. -- Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients ...

Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with ...

(RTTNews) - Argenx SE (ARGX ARGX.BR) announced on Monday that it is discontinuing its Phase 3 UplighTED studies evaluating Efgartigimod PH20 SC in adults with moderate to severe thyroid eye disease, ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every shot in the clinic is destined to land. Now, facing that fact in thyroid eye ...

Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.